New modalities and aspects of antiplatelet therapy for stroke prevention.
Antiplatelet therapy is indicated for secondary prevention of ischaemic stroke. The first-line antiplatelet agent is aspirin. The effect of aspirin is, however, very limited, and this limited effect of aspirin is argued with termed 'aspirin resistance'. Strategies against aspirin resistance may include alternative use of other antiplatelet agents, combination of aspirin with other antiplatelet agents and investigation into molecular targets to develop novel antiplatelet agents. Progress in antiplatelet therapy should be directed at further reducing the risk of ischaemic events including ischaemic stroke without increasing the risk of haemorrhagic events including haemorrhagic stroke.
Department of Neurology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. suchiyam@nij.twmu.ac.jp
Shinichiro
S
Uchiyama
Tomomi
T
Nakamura
Masako
M
Yamazaki
Yumi
Y
Kimura
Makoto
M
Iwata
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D000077407:Cilostazol; D000077144:Clopidogrel; D015195:Drug Design; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000517:prevention & control*; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin